Highest-materiality recent filing
Erasca Q2 net loss $44.1M; ERAS-0015 57% uORR in PDAC; raises $632M
Q2 2026 net loss $44.1M ($0.14/sh) vs $33.9M ($0.12/sh) in Q2 2025; R&D expense $35.9M vs $21.2M.
Erasca prices upsized $550M public offering of 31.4M shares at $17.50
Gross proceeds ~$550M from 31,428,572 shares at $17.50; net proceeds ~$516M.
Erasca reports 57% uORR at 8 weeks for ERAS-0015 in KRAS G12X PDAC; plans pivotal trials in 2027
57% uORR at 8 weeks in 2L+ KRAS G12X PDAC at 32 mg QD RDE (N=7).
Erasca posts Q1 net loss of $183.4M; cash $408.5M; advances ERAS-0015 with robust early data
Net loss of $183.4M ($0.60 per share) vs $31.0M loss a year ago; includes $150M in-process R&D charge for license expansion.
RevMed alleges ERAS-0015 infringes U.S. Patent No. 12,409,225 and misappropriated trade secrets.
Erasca reports positive Phase 1 data for pan-RAS glue ERAS-0015: 62% uORR in 2L+ KRAS G12X NSCLC
62% unconfirmed ORR at 8 weeks in 2L+ KRAS G12X NSCLC at PADs 16-32 mg QD (N=37), exceeding RMC-6236 by 24 ppt.
Erasca reports Q4 2025 net loss $29.1M; ERAS-0015 shows early partial responses
Net loss per share $(0.10) for Q4 2025 vs. $(0.11) in Q4 2024; full-year net loss $124.5M ($0.44/share).
Erasca closes $242.7M upsized public offering; extends cash runway into first half 2029
Preliminary cash, cash equivalents and marketable securities at Dec 31, 2025: ~$341.8M.
Erasca prices upsized public offering of 22.5M shares at $10.00/share, raising $225M gross
Offering of 22.5M shares at $10.00; gross proceeds $225M.
Erasca reports early PRs for ERAS-0015 at 8 mg QD; Phase 1 dose escalation faster than expected
ERAS-0015 AURORAS-1 trial: two confirmed PRs and one unconfirmed PR in patients with different tumor types and RAS mutations at 8 mg QD.
Erasca Q2 2025 net loss $33.9M; cash $386.7M; INDs cleared for two RAS drugs
Net loss of $33.9M ($0.12/sh) for Q2 2025, down from $63.2M ($0.29/sh) in Q2 2024.
Erasca Q1 net loss $31M; cash $411M; IND cleared for ERAS-0015; cash runway to H2 2028
Net loss was $31.0M ($0.11/sh) vs $35.0M ($0.23/sh) in Q1 2024; R&D spend decreased to $26.0M from $28.6M.
Erasca reports FY2024 net loss $161.7M; cash $440.5M; pipeline on track for 2025 IND filings
Net loss for FY2024 $161.7M ($0.69/sh) vs $125.0M ($0.83/sh) in 2023.
Erasca Q3 2024 net loss $31.2M; cash $463.3M; positive Phase 1b naporafenib data
Net loss of $31.2M ($0.11/share) vs $30.4M ($0.20/share) in Q3 2023.
Erasca reports 40% response rate in NRAS Q61X melanoma cohort from Phase 1b SEACRAFT-1 trial
40% (4/10) response rate in efficacy-evaluable NRAS Q61X melanoma patients; 3 confirmed partial responses, 1 unconfirmed.
Erasca Q2 net loss $63.2M; cash $460M; in-licenses RAS drugs, begins Phase 3
Net loss $63.2M ($0.29/share) vs $31.8M ($0.21/share) YOY; R&D $33M including $22.5M in-license payments.
SEACRAFT-2 evaluates pan-RAF inhibitor naporafenib plus MEK inhibitor trametinib vs trametinib alone.
Erasca prices $160M common stock offering of 86.5M shares at $1.85/share
Gross proceeds ~$160M; net proceeds ~$151.6M (or ~$174.4M if underwriters' option exercised).
Erasca signs Joyo/Medshine licenses for pan-RAS/KRAS; cuts 18% staff, deprioritizes ERAS-007
In-licensed pan-RAS inhibitor from Joyo for $12.5M upfront + up to $176.5M milestones; lead candidate ERAS-0015.
Erasca Q1 net loss $35.0M ($0.23/shr); cash $297.7M; naporafenib data shows 13-14 mo median OS
Net loss $35.0M vs $33.2M YoY; EPS $(0.23) vs $(0.22).
Erasca raises $45M in oversubscribed private placement at $2.06/share
Sold 21,844,660 shares at $2.06 each to institutional investors; gross proceeds ~$45M.
Erasca reports FY2023 net loss $125M, cash $322M; clinical updates for naporafenib and ERAS-801
Net loss $125M ($0.83/share) for FY2023 vs $242.8M ($1.99/share) in prior year; R&D expenses $103.8M.
ERAS-007 + encorafenib + cetuximab in BRAF V600E CRC: 40% response (2/5) at 100mg BID-QW, 29% overall across doses.
Erasca Q1 2023 net loss $33.2M; cash $390M; pipeline advances with Phase 3 trial plan
Net loss $33.2M ($0.22/share) vs $36.5M ($0.31/share) year ago; R&D $27.6M, G&A $9.4M.
Erasca reports Phase 1b data for ERAS-601+cetuximab; MTD 40mg BID; tolerable safety
Promising initial safety from Phase 1b FLAGSHP-1 dose escalation for ERAS-601 + cetuximab in advanced solid tumors.
Net loss Q4 2022 $135.3M (incl. $100M in-process R&D for naporafenib license); FY2022 net loss $242.8M ($1.99/share).
Erasca extends cash runway to H2 2025, accelerates naporafenib and ERAS-601 readouts
Cash runway extended from H1 2025 to H2 2025; resources focused on naporafenib and ERAS-007/601 sub-studies.
Erasca licenses naporafenib from Novartis for $100M upfront plus milestones up to $280M
Upfront: $20M cash plus ~$80M in Erasca common stock (private placement, 6-mo lock-up).
Erasca (ERAS) prices $100M public offering and issues $80M stock to Novartis under license
Underwritten offering of 15,384,616 shares at $6.50/share; net proceeds ~$94.7M; expected close Dec 13, 2022.
Erasca Q3 2022 net loss $35.5M; cash $365.5M funds ops into H2 2024
Net loss $35.5M ($0.29/sh) vs $46.1M ($0.46/sh) in Q3 2021; R&D spend $28.2M.
Erasca reports 23% response rate in RAS/MAPK-altered non-CRC tumors; combo trial in H1 2023
23% (6/26) of RAS/MAPK-altered non-CRC solid tumor patients responded to single-agent ERAS-007 or ERAS-601.
Erasca Q2 net loss $35.6M; cash $390.8M; pipeline on track for H2 catalysts
Net loss of $35.6M ($0.30 per share) vs $28.2M ($1.20) year ago; R&D expenses $27.5M, G&A $8.4M.
On April 4, 2023, Wei Lin, M.D. notified Erasca, Inc. (the “Company”) of his decision to resign from his position as Chief Medical Officer of the Company to pursue other opportunities.
Effective as of April 10, 2023, Shannon R. Morris, M.D., Ph.D. has been promoted to the position of the Chief Medical Officer of the Company.
the Board appointed Jean Liu, J.D., to fill such newly created directorship.
Max materiality 0.85 · Median 0.60 · Most common event other_material